Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of ALLN-346 in Hyperuricemic Subjects
NCT04987242Phase 2Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperuricemia and gout comparing ALLN-346 with Placebo (2 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events at 21 days. Started Jul 2021; status: completed.
02
Drugs
ALLN-346
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT04987242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987242.